title: The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain.
authors.affiliation: Servicio de Oftalmología, Hospital de Manises, Manises, Valencia, España. Electronic address: aidanavarro205@gmail.com.
authors.forename: A
authors.initials: A
authors.lastname: Navarro-Navarro
authors.affiliation: Servicio de Oftalmología, Hospital de Manises, Manises, Valencia, España.
authors.forename: D
authors.initials: D
authors.lastname: Salom
authors.affiliation: Servicio de Oftalmología, Hospital General Universitario de Elche, Elche, Alicante, España.
authors.forename: J J
authors.initials: JJ
authors.lastname: Martínez-Toldos
authors.affiliation: Servicio de Oftalmología, Hospital Universitario La Fe, Valencia, España.
authors.forename: P
authors.initials: P
authors.lastname: Udaondo
authors.affiliation: Servicio de Oftalmología, Hospital General Universitario de Elche, Elche, Alicante, España.
authors.forename: C
authors.initials: C
authors.lastname: Fernández-Martínez
authors.affiliation: Servicio de Oftalmología, Hospital de Manises, Manises, Valencia, España.
authors.forename: L
authors.initials: L
authors.lastname: Gutiérrez-Arias
authors.affiliation: Servicio de Oftalmología, Hospital de Manises, Manises, Valencia, España.
authors.forename: A
authors.initials: A
authors.lastname: Hervás
authors.affiliation: Grupo de Biomedicina Molecular, Celular y Genómica, Instituto de Investigación Sanitaria La Fe, Valencia, España.
authors.forename: R
authors.initials: R
authors.lastname: Rodrigo
mesh_terms: D000068258:Bevacizumab / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D003930:Diabetic Retinopathy / Q000188:drug therapy / Q000191:economics*; D006801:Humans; D008269:Macular Edema / Q000188:drug therapy / Q000191:economics*; D000069579:Ranibizumab / Q000191:economics* / Q000627:therapeutic use; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000191:economics* / Q000627:therapeutic use; D013030:Spain
chemical_list: D011993:Recombinant Fusion Proteins; C533178:aflibercept; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab